Genomeditech(Shanghai) Co.LTD

EN

Insights

Press Release

Current position：News > Insights

Insights

TSLP: A Promising Next-Generation Target in Autoimmune Diseases

TSLP is rapidly emerging as one of the most strategically important targets in immunology, driven by its unique role as an upstream regulator of inflammatory pathways. With recent clinical progress, strong commercial validation and a rapidly expanding pipeline are accelerating interest from both global pharma and biotech companies. From monoclonal antibodies to multi-specific formats and long-acting solutions, the diversity of approaches highlights the scale of opportunity ahead.

The IL-17 Pathway Revisited: Mechanistic Maturity and Emerging Opportunities in Immunology

The IL-17 pathway is re-entering the spotlight as new clinical data and mechanistic insights drive the shift from single IL-17A inhibition to dual IL-17A/F targeting.

This article highlights how cytokine redundancy is shaping next-generation therapies, while a mature target continues to evolve across indications and global markets.

Explore how incremental innovation is unlocking new differentiation in one of immunology’s most established pathways.

IL-4 vs. IL-13: Who Will Lead the Next Wave of Autoimmune Therapies?

IL-4 and IL-13 are emerging as central drivers of type 2 inflammation—and the race to target this pathway is accelerating. With blockbuster biologics reshaping the autoimmune therapy market and new approvals continuing to expand their clinical reach, the IL-4/IL-13 axis has quickly become one of the most competitive areas in global immunology R&D. As next-generation approaches begin to emerge, a key question is taking shape across the industry: which pathway will define the next wave of autoimmune therapies?

IL-23: A Rising Target in Autoimmune Disease

TNF-α: Renewed Focus in Autoimmune Disease Therapy

Autoimmune diseases affect millions, and unmet needs remain high. TNF-α inhibitors are a cornerstone of therapy, and innovation continues.

Sorriso Pharmaceuticals’ oral bispecific antibody SOR102 targets TNF-α and IL-23p19 and shows promising safety and early efficacy in ulcerative colitis—offering a more convenient, gut-focused alternative to injectable therapies.

Global efforts in TNF/TNFR-targeted therapies—from receptor-selective drugs to fusion proteins—are redefining treatment possibilities for autoimmune diseases.

PD-1 Agonists: Insights into Their Growing Impact

PD-1 has long been a milestone target in cancer immunotherapy, with PD-1/PD-L1 inhibitors driving major advances in oncology. Now, the same pathway is being explored from the opposite angle: PD-1 agonists for autoimmune diseases. By enhancing immune inhibition, these therapies aim to suppress overactive T cells, addressing conditions such as rheumatoid arthritis, SLE, and primary Sjogren’s syndrome.

Will B7-H3 Become the Next Major ADC Target?

The B7-H3 (CD276) ADC field is heating up in 2026. Recent deals—DualityBio & Roche, InnoLake & Ellipses Pharma—highlight global interest and the therapeutic potential of this target.

B7-H3 is overexpressed in multiple solid tumors and contributes to immune evasion. ADCs targeting B7-H3 are showing promising early clinical activity, with several programs advancing into Phase III trials, including YL201, HS-20093, and inatamab deruxtecan. Combination strategies with PD-(L)1 inhibitors are also expanding the potential of this target.

IL-5: a key regulator of eosinophilic inflammation

Interleukin-5 (IL-5) is a key driver of eosinophilic inflammation, underlying conditions such as severe asthma, chronic rhinosinusitis with nasal polyps, and other allergic or inflammatory diseases. Recent advances in IL-5–targeted therapies, including GSK’s next-generation ultra-long-acting antibody Depemokimab (Exdensur), are transforming the treatment landscape. With extended dosing intervals and proven efficacy, these therapies offer new hope for improved patient outcomes and quality of life.

IL-5: a key regulator of eosinophilic inflammation

Interleukin-5 (IL-5) is a key driver of eosinophilic inflammation, underlying conditions such as severe asthma, chronic rhinosinusitis with nasal polyps, and other allergic or inflammatory diseases. Recent advances in IL-5–targeted therapies, including GSK’s next-generation ultra-long-acting antibody Depemokimab (Exdensur), are transforming the treatment landscape. With extended dosing intervals and proven efficacy, these therapies offer new hope for improved patient outcomes and quality of life.

Could GDF15 Become the Next Super Target After PD-1 and GLP-1?

A recent Nature Aging study reveals that senescent tumor-adjacent epithelial cells secrete GDF15, driving colorectal cancer progression via a metabolic–epigenetic feedback loop. This expands GDF15’s role beyond tumor cells to its influence on the surrounding microenvironment.

Emerging as a hub connecting tumor growth, immune evasion, and systemic metabolism, GDF15 is a promising target across oncology, cancer cachexia, obesity, and metabolic diseases. Monoclonal antibodies like Ponsegromab and Visugromab are showing encouraging results in early clinical trials.

First Prev 1 2 3 4 5 Next Last

Total 8 Page

Jump

Current position：News > Insights

classify

Insights

TSLP: A Promising Next-Generation Target in Autoimmune Diseases

TSLP is rapidly emerging as one of the most strategically important targets in immunology, driven by its unique role as an upstream regulator of inflammatory pathways. With recent clinical progress, strong commercial validation and a rapidly expanding pipeline are accelerating interest from both global pharma and biotech companies. From monoclonal antibodies to multi-specific formats and long-acting solutions, the diversity of approaches highlights the scale of opportunity ahead.

The IL-17 Pathway Revisited: Mechanistic Maturity and Emerging Opportunities in Immunology

The IL-17 pathway is re-entering the spotlight as new clinical data and mechanistic insights drive the shift from single IL-17A inhibition to dual IL-17A/F targeting.

This article highlights how cytokine redundancy is shaping next-generation therapies, while a mature target continues to evolve across indications and global markets.

Explore how incremental innovation is unlocking new differentiation in one of immunology’s most established pathways.

IL-4 vs. IL-13: Who Will Lead the Next Wave of Autoimmune Therapies?

IL-4 and IL-13 are emerging as central drivers of type 2 inflammation—and the race to target this pathway is accelerating. With blockbuster biologics reshaping the autoimmune therapy market and new approvals continuing to expand their clinical reach, the IL-4/IL-13 axis has quickly become one of the most competitive areas in global immunology R&D. As next-generation approaches begin to emerge, a key question is taking shape across the industry: which pathway will define the next wave of autoimmune therapies?

IL-23: A Rising Target in Autoimmune Disease

TNF-α: Renewed Focus in Autoimmune Disease Therapy

Autoimmune diseases affect millions, and unmet needs remain high. TNF-α inhibitors are a cornerstone of therapy, and innovation continues.

Sorriso Pharmaceuticals’ oral bispecific antibody SOR102 targets TNF-α and IL-23p19 and shows promising safety and early efficacy in ulcerative colitis—offering a more convenient, gut-focused alternative to injectable therapies.

Global efforts in TNF/TNFR-targeted therapies—from receptor-selective drugs to fusion proteins—are redefining treatment possibilities for autoimmune diseases.

PD-1 Agonists: Insights into Their Growing Impact

PD-1 has long been a milestone target in cancer immunotherapy, with PD-1/PD-L1 inhibitors driving major advances in oncology. Now, the same pathway is being explored from the opposite angle: PD-1 agonists for autoimmune diseases. By enhancing immune inhibition, these therapies aim to suppress overactive T cells, addressing conditions such as rheumatoid arthritis, SLE, and primary Sjogren’s syndrome.

Will B7-H3 Become the Next Major ADC Target?

The B7-H3 (CD276) ADC field is heating up in 2026. Recent deals—DualityBio & Roche, InnoLake & Ellipses Pharma—highlight global interest and the therapeutic potential of this target.

B7-H3 is overexpressed in multiple solid tumors and contributes to immune evasion. ADCs targeting B7-H3 are showing promising early clinical activity, with several programs advancing into Phase III trials, including YL201, HS-20093, and inatamab deruxtecan. Combination strategies with PD-(L)1 inhibitors are also expanding the potential of this target.

IL-5: a key regulator of eosinophilic inflammation

Interleukin-5 (IL-5) is a key driver of eosinophilic inflammation, underlying conditions such as severe asthma, chronic rhinosinusitis with nasal polyps, and other allergic or inflammatory diseases. Recent advances in IL-5–targeted therapies, including GSK’s next-generation ultra-long-acting antibody Depemokimab (Exdensur), are transforming the treatment landscape. With extended dosing intervals and proven efficacy, these therapies offer new hope for improved patient outcomes and quality of life.

IL-5: a key regulator of eosinophilic inflammation

Interleukin-5 (IL-5) is a key driver of eosinophilic inflammation, underlying conditions such as severe asthma, chronic rhinosinusitis with nasal polyps, and other allergic or inflammatory diseases. Recent advances in IL-5–targeted therapies, including GSK’s next-generation ultra-long-acting antibody Depemokimab (Exdensur), are transforming the treatment landscape. With extended dosing intervals and proven efficacy, these therapies offer new hope for improved patient outcomes and quality of life.

Could GDF15 Become the Next Super Target After PD-1 and GLP-1?

A recent Nature Aging study reveals that senescent tumor-adjacent epithelial cells secrete GDF15, driving colorectal cancer progression via a metabolic–epigenetic feedback loop. This expands GDF15’s role beyond tumor cells to its influence on the surrounding microenvironment.

Emerging as a hub connecting tumor growth, immune evasion, and systemic metabolism, GDF15 is a promising target across oncology, cancer cachexia, obesity, and metabolic diseases. Monoclonal antibodies like Ponsegromab and Visugromab are showing encouraging results in early clinical trials.

MORE

Insights

Press Release

Message consultation

                    
Toll-free hotline：400-627-9288
                    
Email address：mkt.genomeditech@gmail.com

Company address：5th Floor, Building 1, Lane 299, Kangwei Road, Pudong New District, Shanghai

Copyright © 2023 吉满生物科技（上海）有限公司 All rights reserved.

Message

Message consultation